These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17961195)

  • 1. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?
    Aagaard L; Soendergaard B; Stenver DI; Hansen EH
    Br J Clin Pharmacol; 2008 Mar; 65(3):364-76. PubMed ID: 17961195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
    Li X; Lin X; Ren H; Guo J
    J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Three Different Data Sources of Adverse Drug Reactions Using Adverse Drug Reaction Data of Fluorouracil for Gastric Cancer as an Example.
    Niu R; Chen Y; Xiang Y; Liu Y; Guo J; Feng B
    Biol Pharm Bull; 2020; 43(10):1476-1480. PubMed ID: 32999157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues.
    Hasford J; Bruchmann F; Lutz M; Thürmann P; Schmiedl S
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1697-1704. PubMed ID: 34143228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
    Ortega A; Aguinagalde A; Lacasa C; Aquerreta I; Fernández-Benítez M; Fernández LM
    Ann Pharmacother; 2008 Oct; 42(10):1491-6. PubMed ID: 18780808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.
    Aagaard L; Hansen EH
    BMC Clin Pharmacol; 2009 Mar; 9():4. PubMed ID: 19254390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety learning from drugs of the same class: room for improvement.
    Stefansdottir G; Knol MJ; Arnardottir AH; van der Elst ME; Grobbee DE; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2012 May; 91(5):872-80. PubMed ID: 22453192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of discrepancies between adverse drug reactions coded by medical records technicians and those reported by the pharmacovigilance team in pediatrics: An intervention to improve identification, reporting, and coding.
    Soyer J; Necsoiu D; Desjardins I; Lebel D; Bussières JF
    Arch Pediatr; 2019 Oct; 26(7):400-406. PubMed ID: 31611146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study.
    Johansson ML; Hägg S; Wallerstedt SM
    BMC Clin Pharmacol; 2011 Sep; 11():14. PubMed ID: 21899766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADR in Journals: Are They Translated into Regulatory Frameworks?
    Kolupoti A; Chakraborty A; Shahistha K
    Curr Drug Saf; 2022; 17(1):34-39. PubMed ID: 34151768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bias in spontaneous reporting of adverse drug reactions in Japan.
    Matsuda S; Aoki K; Kawamata T; Kimotsuki T; Kobayashi T; Kuriki H; Nakayama T; Okugawa S; Sugimura Y; Tomita M; Takahashi Y
    PLoS One; 2015; 10(5):e0126413. PubMed ID: 25933226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway.
    Gedde-Dahl A; Harg P; Stenberg-Nilsen H; Buajordet M; Granas AG; Horn AM
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):999-1005. PubMed ID: 17457794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
    J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain.
    Sweis D; Wong IC
    Drug Saf; 2000 Aug; 23(2):165-72. PubMed ID: 10945377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system].
    Egger SS; Krähenbühl S; Schlienger RG
    Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.